Frequency Therapeutics, Inc. (FREQ) 


Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Frequency Therapeutics, Inc. ("Frequency" or "the Company") (NASDAQ: FREQ).  The investigation concerns whether Frequency and certain of its officers and/or directors have violated federal securities laws.


On or around October 2, 2019, Frequency conducted its initial public offering (“IPO”), selling 6,000,000 shares of common stock priced at $14.00 per share.  On March 23, 2021, Frequency issued a press release announcing topline, day-90 data from its FX-322 Phase 2a study (FX-322-202).  Frequency disclosed that “[t]he interim results show that four weekly injections in subjects with mild to moderately severe sensorineural hearing loss (SNHL) did not demonstrate improvements in hearing measures versus placebo.”  On this news, Frequency’s stock price fell $28.30 per share, or 77.98%, to close at $7.99 per share on March 23, 2021.


If you are aware of any facts relating to this investigation, or purchased Frequency shares, you can assist this investigation by visiting contacting the firm. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

© 2020 Bronstein, Gewirtz & Grossman, LLC

  • Twitter Social Icon
  • LinkedIn

BG&G is not affiliated to any of these companies. All respective trademarks are owned by the respective companies.